Clinical Trials Logo
  1. Home
  2. Liver Transplantation
  3. NCT03781414

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension — CONTRAIL I  

Liver Transplant Rejection Clinical Trial

Official title:
A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Two Regimens of Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-month Additional Follow-up and a Long-term Extension (CONTRAIL I)

Clinical Trial Summary

The purpose of this study was to investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 dose regimens in liver transplant recipients.

Clinical Trial Description

This study allowed assessment of the ability of CFZ533 to replace Calcineurin inhibitors (CNIs) in terms of anti-rejection efficacy, while providing potentially better renal function with an expected similar safety and tolerability profile. Results of this study will inform the CFZ533 dose and regimen selection for investigation in later phases of clinical development. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03781414
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date October 7, 2019
Completion date April 20, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT01678937 - Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents N/A
Recruiting NCT02260375 - MSC Therapy in Liver Transplantation Phase 1
Not yet recruiting NCT04514666 - VOCs in Kidney and Liver Transplants N/A
Not yet recruiting NCT05335551 - TRU-IMMUNO: Optimizing Liver Immunosuppression
Completed NCT01745731 - Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration Phase 2
Enrolling by invitation NCT05082077 - Global Utilization And Registry Database for Improved preservAtion of doNor Livers
Completed NCT06060808 - Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.
Completed NCT03874286 - The TOGETHER Project - Liver
Completed NCT04789213 - Mortality, Morbidity and Risk Factors of Liver Retransplantation
Recruiting NCT06400771 - Safety of DNP007 in Healthy Subjects Phase 1
Recruiting NCT03603548 - Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial N/A
Withdrawn NCT03315052 - Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects Phase 4
Enrolling by invitation NCT05655273 - Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients Phase 4
Active, not recruiting NCT05325073 - Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients Phase 4
Recruiting NCT05707520 - Long-term Benefit of MPA in Liver Transplantation
Recruiting NCT04657562 - The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma
Completed NCT01444079 - Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation N/A
Active, not recruiting NCT06153641 - Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients